
Duane Lawrence
Mirada Medical Chairman, Duane Lawrence, brings with him successful runs leading both high-growth HealthTech SMEs, mid-market publicly traded global technology and service businesses across five continents. A 30-year veteran of the healthcare industry and a US and UK citizen based in the UK, Duane has specialised in building and developing strong teams, recognising emerging opportunities in markets and building programmes and products to successfully fill those opportunities since 2003.
From February 2015 to June 2017, Duane was Managing Director at EMIS Health, the global HealthTech software and services business. Prior to that, Duane was the CEO of InferMed, having joined the Board in May 2007, leading it through to its successful trade exit in 2015.
Prior to this, Duane was GM of Misys Healthcare Systems International Ltd, with responsibility for the company’s operations outside of North America.
A business and finance graduate of the University of Notre Dame in the US, Duane’s successful track record of global commercial leadership is now being shared with HealthTech SMEs and mid-market companies through advisory and NED roles.

Gene Saragnese
Having served as Mirada Chairman since 2015 for over 4 years, Gene Saragnese remains a member of the Board. He was CEO of Philips Imaging Systems from April 2009 until May 2015 and prior to joining Philips, Mr. Saragnese served as GE Healthcare’s Vice President and General Manager of Molecular Imaging and Computed Tomography. He previously served as Chief Technology Officer for GE Healthcare. In this role, Mr. Saragnese led Global Product Development Engineering and Component Operations around the world, including Corporate Research sites in New York, China, India, and Germany. He has also served as General Manager for GE Medical Systems’ Global MRI business and the leader for GE Medical Systems’ Global MRI Engineering organization. Prior to his career in healthcare, Mr. Saragnese held management roles with GE, RCA, Martin Marietta and Lockheed Martin in the aerospace industry. He is a graduate of Rutgers College of Engineering in New Jersey.

Hugh Bettesworth
Hugh Bettesworth has worked in the software industry for over fifteen years, the last twelve in the clinical sector. He joined Mirada in 2001, and took over the development of the company’s image fusion product lines in 2003. Following Mirada’s acquisition by first CTI Molecular Imaging and then Siemens Molecular Imaging, Hugh continued to develop the market for these products, focusing on the delivery of specialist molecular imaging workflows into new markets and in particular the PACS market. He led a management buyout in 2008 which re-established Mirada’s independent status and provided the platform for the innovative software developments that have resulted in Mirada’s subsequent growth and leading technical position today.

David Gudgin
David Gudgin qualified as a management accountant with ICL before spending 3 years at the BBC. In 1999 he joined 3i as an investor in European technology based in London and Amsterdam. In 2002 he moved to Foursome Investments (now Frog Capital) as the lead investor of two funds, an environmental technology fund and a later stage development capital fund. David joined Close Ventures in 2005 and became a partner in Albion Ventures in 2009. David has a BSc in Economics from Warwick University.

Sam Gray
Sam joined Apposite Capital in 2007. He has been particularly involved in all of Apposite’s healthcare services and health IT investments and served on portfolio Boards in both the US and Europe. In addition to Mirada Medical, Sam currently serves on the Board of Medical Imaging Partnership, MC Care Holdings, Summit Medical, Swanton Care and was a Board Director of CancerPartnersUK, By the Bridge, SureCalm and WellPartner. Sam has been involved in deal-making in the healthcare sector since 2000 when he joined Deutsche Bank’s mergers and acquisitions practice, working with a number of multinational clients on corporate divestitures and acquisitions, including public takeovers and leveraged buy-outs. Sam then joined the Business Development team at Belgian pharmaceutical company, UCB, where he was instrumental in global product licensing and M&A, including UCB’s $2.7bn acquisition of the UK public biotech company, Celltech. Sam has a first degree in Natural Sciences and a masters degree in Chemistry from Cambridge University, as well as an MBA from Harvard Business School.

Seb Jantet
Seb Jantet, Mirada’s Chief Financial and Operations Officer has over 25 years of experience in finance, both in the public and private markets. Most recently he was Chief Financial Officer of Induction Healthcare PLC, during which time he steered the company through an AIM IPO, raising just under £17m from investors. Prior to that he was Chief Financial officer of DrugDev Inc, which he joined in 2013 and was part of the team that executed a buy and build strategy in the clinical trials technology market, ultimately culminating in a successful exit to IQVIA in 2017. Seb also spent 22 years working in the City, 11 years of which working at Investec as a top-ranked healthcare analyst and headed up the healthcare equity research team. Prior to that, he worked 4 years for KPMG working in corporate finance. Seb is a qualified accountant, a member of the Institute of Chartered Accountants of England and Wales and has a BA in French and Politics from the University of East Anglia. He is also a non-executive director of Elizabeth Finn Homes Limited.